Follow
← Back
Medicines · Interactions

Levodopa — interactions

Other medicines, foods and herbal products can change how Levodopa works. Everything on this page comes from Levodopa's own FDA-approved label — the same source as the main guide.

← Back to the full Levodopa guide

⚠ Caution: Monitor patients on MAO-B inhibitors for orthostatic hypotension Dopamine D2 antagonists, isoniazid, and iron salts: May reduce the effectiveness of INBRIJA

Medicines named in Levodopa's label

Grouped the way the label groups them. Each name links to that medicine's NepalDoc guide; where the label names a class instead of a medicine, the label's words are quoted.

Monoamine Oxidase (MAO) Inhibitors

The use of nonselective MAO inhibitors with INBRIJA is contraindicated . Discontinue use of any nonselective MAO inhibitors at least two weeks prior to initiating INBRIJA. The use of selective MAO-B inhibitors with INBRIJA may be associated with orthostatic hypotension. Monitor patients who are taking these drugs concurrently.

Dopamine D2 Receptor Antagonists and Isoniazid

Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone, metoclopramide) and isoniazid may reduce the effectiveness of levodopa. Monitor patients for worsening Parkinson's symptoms.

Iron Salts

Iron salts or multivitamins containing iron salts can form chelates with levodopa and consequently reduce the bioavailability of levodopa.

Levodopa's label names 4 medicines that NepalDoc also covers.

Their interaction pages

These medicines named in Levodopa's label have interaction pages of their own:

Read the full interactions section from Levodopa's label

Monitor patients on MAO-B inhibitors for orthostatic hypotension Dopamine D2 antagonists, isoniazid, and iron salts: May reduce the effectiveness of INBRIJA

7.1 Monoamine Oxidase (MAO) Inhibitors The use of nonselective MAO inhibitors with INBRIJA is contraindicated . Discontinue use of any nonselective MAO inhibitors at least two weeks prior to initiating INBRIJA. The use of selective MAO-B inhibitors with INBRIJA may be associated with orthostatic hypotension. Monitor patients who are taking these drugs concurrently.

7.2 Dopamine D2 Receptor Antagonists and Isoniazid Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone, metoclopramide) and isoniazid may reduce the effectiveness of levodopa. Monitor patients for worsening Parkinson's symptoms.

7.3 Iron Salts Iron salts or multivitamins containing iron salts can form chelates with levodopa and consequently reduce the bioavailability of levodopa.

Levodopa guide · All interaction pages · Medicines A–Z

SourcesU.S. FDA-approved label via DailyMed (label effective 20 Jul 2026) · National List of Essential Medicines, Nepal (2021) · U.S. labeling may differ from Nepal DDA-approved labeling and local prescribing practice.

This page summarises Levodopa's FDA-approved label for information — it is not medical advice. Always tell your doctor or pharmacist about every medicine, supplement and herbal product you take.

Search medicines in the app / एपमा औषधि खोज्नुहोस् Find a pharmacy / फार्मेसी खोज्नुहोस्
+ Safety information

This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.

Share this Medicine
NepalDoc — Nepal's Healthcare Super-App (Beta) / नेपालको स्वास्थ्य सुपर-एप (बेटा).
Medicine information only — not medical advice. Confirm with a pharmacist or doctor.